Prosecution Insights
Last updated: July 17, 2026

Examiner: ONDACHI, PAULINE WANJIKU MUCH

Tech Center 1600 • Art Units: 1627

This examiner grants 0% of resolved cases

Performance Statistics

Allow Rate
-60.0% vs TC avg
4
Total Applications
Interview Lift
0
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
0%
§102 Novelty
59.1%
§103 Obviousness
18.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18720994 FUNGICIDAL COMPOSITIONS Non-Final OA SYNGENTA CROP PROTECTION AG
18705175 TOLL-LIKE RECEPTOR AGONISTS AND ANTAGONISTS AND USES THEREOF Non-Final OA Regents of the University of Minnesota
18393205 ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF Non-Final OA XinThera, Inc.
18542910 PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN Non-Final OA Boehringer Ingelheim International GmbH
18704872 CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS Non-Final OA Insmed Incorporated
18391649 Method for Promoting Functional Cure of AIDS by Reducing HIV Reservoir with Lenalidomide Non-Final OA The First Affiliated Hospital Zhejiang University School of Medicine

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month